The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy

Cancer Gene Therapy

Volumn 22, Issue 3, 2015, Pages 154-162

  De Vries, C R ^a   Monken, C E ^b   Lattime, E C ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINIA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER THERAPY; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TH1 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINIA VIRUS; ANIMAL; BONE MARROW CELL; CANCER TRANSPLANTATION; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; GENETICS; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; PROTO ONCOGENE; TRANSGENIC MOUSE; TUMOR CELL LINE; VACCINATION;

MUS; VACCINIA VIRUS;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CLONAL ANERGY; FEMALE; GENES, ERBB-2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VACCINATION; VACCINIA VIRUS;

EID: 84927691726     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.2     Document Type: Article

References (42)

1. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-760.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987; 235: 177-182.
4. Ostrand-Rosenberg S. Myel oid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-1600.
5. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
6. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
7. Youn J-I, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leuk Biol 2012; 91: 167-181.
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
9. Li Z, Pang Y, Gara SK, Achyut BR, Heger C, Goldsmith PK et al. Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-beta in breast cancer progression. Int J Cancer 2012; 131: 2584-2595.
10. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2009; 70: 68-77.
11. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828-835.
12. Takaku S, Terabe M, Ambrosino E, Peng J, Lonning S, McPherson JM et al. Blockade of TGF-[beta] enhances tumor vaccine efficacy mediated by CD8+ T cells. Int J Cancer 2009; 126: 1666-1674.
13. Goulart MR, Pluhar GE, Ohlfest JR. Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer. PloS One 2012; 7: e33274-e33274.
14. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill Ma et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother 2011; 60: 1269-1279.
15. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocytemediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752.
16. Lee SS et al. Intravesical gene therapy: vaccinia virus recombinants transfect murine bladder tumors and urothelium. Proceedings of the American Association for Cancer Research 1993; 34: 337. abstract 2005.
17. Mastrangelo MJ, Maguire HC, McCue PA, Lee SS, A A, LN N. A pilot study demonstrating the feasibility of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res 1995; 4: 55-69.
18. Mastrangelo MJ, Maguire HC Jr., Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422.
19. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 2012; 20: 749-758.
20. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQM et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 7102-7362.
21. Yang AS, Monken CE, Lattime EC. Intratumoral vaccination with vacciniaexpressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigen. Cancer Res 2003; 63: 6956-6961.
22. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997; 23: 1094-1097.
23. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992; 175: 481-487.
24. Bargmann CI, Hung M-C, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-657.
25. Rusciano D, Burger MM. Cancer metastasis: experimental approaches (laboratory techniques in biochemistry and molecular biology). In: Welch DR (ed.) Cancer Metastasis: Experimental Approaches. Elsevier Science Publishing Co.: Amsterdam, Netherlands, 2000.
26. McAveney KM, Gomella LG, Lattime EC. Induction of TH1-and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 1994; 39: 401-406.
27. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT et al. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/ neu-transgenic mice. J immunol 2003; 170: 4273-4280.
28. Nikitczuk KP. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN response and enhances survival. J Cancer Ther 2013; 04: 280-290.
29. Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood 2011; 117: 5381-5390.
30. Abe F, Dafferner AJ, Donkor M, Westphal SN, Scholar EM, Solheim JC et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol Immunother 2010; 59: 47-62.
31. Riggs DR, Jackson B, Vona-Davis L, McFadden D. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin. J Surg Res 2002; 108: 279-284.
32. Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007; 13: 4170-4177.
33. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21: 822-835.
34. Kudo-Saito C, Schlom J, Hodge JW. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 2004; 10: 1090-1099.
35. Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother 2013; 62: 1521-1531.
36. Repaka A, Ea Poplin, August Da, Ben-Menachem T, Michael H, Artymyshyn R et al. 350 Phase I trial of endoscopic ultrasound (EUS) guided intratumoral vaccination with recombinant Panvac-F and systemic Panvac-V in patients with locally advanced pancreatic cancer. Gastrointest Endosc 2013; 77: 43.
37. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14: 559-567.
38. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
39. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12: 6737-6747.
40. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718-730.
41. Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPVspecific antitumor effects. Cancer Immunol Immunother 2013; 62: 1175-1185.
42. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Translat Med 2014; 6: 226ra32.